Patents by Inventor Martina GEIGER

Martina GEIGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416411
    Abstract: The present invention generally relates to bispecific antibodies that bind to CD3 and Folate Receptor 1 (FolR1), e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: December 15, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Martina GEIGER, Christian KLEIN, Alexander KNAUPP
  • Publication number: 20230416366
    Abstract: The present invention relates to anti-CD3/anti-CD28 bispecific antigen binding molecules and masked protease activated forms thereof, methods for their production, pharmaceutical compositions containing these molecules, and their use as immunomodulators and/or costiumulators in the treatment of a disease, in particular cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Martina GEIGER, Thomas HOFER, Christian KLEIN, Pablo UMA√ĎA
  • Publication number: 20230357431
    Abstract: The present invention generally relates to activatable antigen binding receptors capable of specific binding to a mutated Fc domain. The antigen binding receptors of the invention are activatable through (a) protease(s). After activation, the antigen binding receptors are targeted to tumor cells by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. The invention also relates to transduced immune cells expressing the antigen binding receptors of the invention and/or nucleic acid molecules encoding the antigen binding receptors of the present invention. Further provided are kits comprising such cells and/or nucleic acid molecules in combination with tumor targeting antibodies comprising a mutated Fc domain.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Diana DAROWSKI, Martina GEIGER, Christian KLEIN
  • Publication number: 20230287145
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: December 15, 2022
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alejandro CARPY GUTIERREZ CIRLOS, Anne FREIMOSER-GRUNDSCHOBER, Martina GEIGER, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Christiane NEUMANN
  • Publication number: 20230119537
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 20, 2023
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Patent number: 11547748
    Abstract: The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, ?? T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: January 10, 2023
    Inventors: Christian Klein, Claudio Sustmann, Gerhard Niederfellner, Martina Geiger, Stefan Endres, Sebastian Kobold
  • Publication number: 20220275087
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: December 2, 2021
    Publication date: September 1, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Patent number: 11242390
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Rebecca Croasdale-Wood, Christian Klein, Juergen Michael Schanzer, Kay-Gunnar Stubenrauch, Pablo Umana, Martina Geiger, Eric Sullivan, Jigar Patel
  • Publication number: 20200116727
    Abstract: The present invention relates to a new cell-based assay for determining antigen expression in primary tumor samples. The method further relates to the determination of antigen and protease expression in primary tumor samples. The method allows robust determination of antigen and/or protease expression without the need to digest the tumor samples. The method further allows for selection of antibodies and for selection of protease-cleavable linkers for the treatment of tumors.
    Type: Application
    Filed: June 12, 2019
    Publication date: April 16, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martina GEIGER, Christian KLEIN
  • Publication number: 20190216908
    Abstract: The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, ?? T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described.
    Type: Application
    Filed: June 30, 2017
    Publication date: July 18, 2019
    Inventors: Christian Klein, Claudio Sustmann, Gerhard Niederfellner, Martina Geiger, Stefan Endres, Sebastian Kobold
  • Publication number: 20190119383
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: September 21, 2018
    Publication date: April 25, 2019
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL